drugset

Drugs / Acumapimod

Follow last change Nov 2019 re-read 3 minutes ago

Acumapimod

also known as BCT197

Developed for: chronic obstructive pulmonary disease
Investigated by: Mereo BioPharma · Novartis

Trials 1

today NCT01332097 · Ph 2

20112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01332097	Mar 2011 → May 2013	chronic obstructive pulmonary disease	Mereo BioPharma	Completed	Missed primary

Press releases naming this drug 1 release

Date	Issuer	Release
2017-12-11	Mereo BioPharma	Mereo announces positive top-line results from Phase 2 trial with BCT-197 (acumapimod) mereobiopharma.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Acumapimod	“Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).” PMID 31682162 ↗ Nov 2019
Known as	BCT197	“Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD.” PMID 31682162 ↗ Nov 2019
Action	Inhibit	“Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).” PMID 31682162 ↗ Nov 2019
Route	Oral	“Acumapimod is a potent, selective, oral, p38 inhibitor under investigation for treatment of acute exacerbations of COPD (AECOPD).” PMID 31682162 ↗ Nov 2019